Business Wire

Altasciences Wins Most Successful Early Phase Research (Preclinical & Phase I) at the 2019 CARE Awards

Share

Altasciences won in the Most Successful Early Phase Research (Preclinical & Phase I) category at the 2019 Clinical and Research Excellence (CARE) Awards. The award win was announced during a ceremony presented by Ben Nemzer at the Hyatt Regency Boston, US on May 2, 2019.

Now in its fourth year, the CARE Awards drew a crowd of pharmaceutical and biomedtech industry leaders and innovators from companies both large and small, who gathered to celebrate the achievements of those working to advance the quality of healthcare worldwide by bringing new and needed medicines to market. Categories for the awards spanned the full spectrum of the drug development process, and the winners of these prestigious trophies were as diverse as the categories themselves.

Altasciences undertook an innovative approach to identify and recruit asymptomatic patients with nonalcoholic steatohepatitis or NASH, a disease for which recruitment competition is quite high. This project required creative and insightful thinking, analysis and preparation to proactively build a patient database for a condition that is asymptomatic, for which affected patients lack awareness and hence motivation to participate in a clinical trial. The upfront investment of effort paid off. Despite joining the trial 2 months behind other sites, Altasciences became the top enrolling site, recruiting more than 35% of the overall patients.

I am proud of our team’s unwavering commitment and passion to bringing better and more cost effective drugs to the people who need them, faster. This recognition by the industry of our ability to provide innovative solutions and of our effective participant recruitment and retention strategies reflects Altasciences’ ongoing drive to meet and exceed sponsor expectations,” stated Chris Perkin, CEO, at Altasciences.

To see the full list of CARE Awards winners please visit: https://pharmaintelligence.informa.com/events/awards/care-awards-2019

About Altasciences
Altasciences is a forward-thinking, mid-size contract research organization offering pharmaceutical and biotechnology companies of all sizes a proven, flexible approach to preclinical and early phase clinical studies, from lead candidate selection to proof of concept. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.

About Informa Pharma Intelligence
Trusted by over 3,000 of the world’s leading pharmaceutical companies, CROs, med and biotech organizations, and healthcare service providers, the Pharma Intelligence suite of intelligence solutions delivers vital, accurate, and timely intelligence about the drug development pipeline to pharmaceutical and biomedical decision makers around the world. At Pharma Intelligence, global teams of subject area experts follow and analyze key diseases, clinical trials, drug approvals and R&D activities as part of the breadth and depth of data available to customers.

Contact information

Julie-Ann Cabana
Altasciences
913 304-4505
jcabana@altasciences.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Moody’s Analytics Wins Best Reporting System Provider in Waters Rankings23.7.2019 15:30:00 CESTPress release

Moody’s Analytics, a global provider of financial intelligence, has won the award for Best Reporting System Provider in the 2019 Waters Rankings. We earned this recognition for our regulatory reporting solution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190723005679/en/ For banks and insurers, staying on top of regulatory changes is critical. Our end-to-end solution handles the entire reporting process, producing 3,000 different regulatory reports covering more than 50 jurisdictions. It automatically delivers all required updates well in advance of the relevant deadlines and makes it easy for clients to review, adjust, audit, and validate their reports. The Moody’s Analytics regulatory surveillance team boasts a wealth of experience in both local and international domains going back decades. They monitor more than 100 supervisor websites to ensure that our clients receive the updates they need in a timely fashion. “Regu

Gilead Presents New Findings on Profile of Descovy® for Potential Use as HIV Pre-exposure Prophylaxis Compared With Truvada®23.7.2019 15:00:00 CESTPress release

Gilead Sciences, Inc. (NASDAQ: GILD) today presented additional results from the DISCOVER trial evaluating an investigational use of Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets; F/TAF) for HIV pre-exposure prophylaxis (PrEP). In a sub-analysis of the DISCOVER trial, Descovy reached intracellular drug concentration levels above the estimated protective threshold significantly more quickly than Truvada (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg tablets; F/TDF), and additional pharmacokinetic data confirm that these drug concentration levels persist longer than Truvada. The results were presented at the 10th International AIDS Society Conference on HIV Science (IAS 2019) being held in Mexico City. “Gilead is committed to driving advances in HIV prevention and supporting broader public health initiatives that are designed to reduce HIV infections,” said Diana Brainard, MD, Senior Vice President, HIV and Emerging Viruses, Gilead Sciences. “These

Velodyne Lidar Acquires Mapper.ai for ADAS Launch23.7.2019 15:00:00 CESTPress release

Velodyne Lidar, Inc. today announced it has acquired mapping and localization software as well as intellectual property assets from Mapper.ai. Mapper technology will enable Velodyne to accelerate development of Vella™, breakthrough software that establishes its directional view Velarray™ lidar sensor. The Velarray is the first solid-state Velodyne lidar sensor that is embeddable and fits behind a windshield, as an integral component for superior, more effective advanced driver assistance systems (ADAS). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190723005257/en/ In addition to ADAS, Velodyne will incorporate Mapper technology into lidar-centric solutions for other emerging applications, including autonomous vehicles, last-mile delivery services, security, smart cities, smart agriculture, robotics, and unmanned aerial vehicles. (Photo: Business Wire) Mapper’s entire leadership and engineering teams will join Velodyne, bol

Wealthy Americans are increasingly willing to invest, new UBS survey finds23.7.2019 14:12:00 CESTPress release

US high net worth individuals and business owners are expressing growing intentions to invest as US markets continue to hit record highs in 2019, according to UBS Global Wealth Management's new quarterly Investor Sentiment survey. The survey, which polled more than 3,800 wealthy investors and entrepreneurs in 17 countries, also shows US investors remain positive on the U.S. stock market but continue to rank politics and the national debt as top concerns. Fifty percent of US investors see a diversified portfolio as a hedge against US-China trade tensions specifically, in line with UBS GWM's own views, compared with 41% who favor cash. Filippo Ilardi, US Client Strategy Officer at UBS Global Wealth Management, says: "We are pleased to see a substantial increase in investors willing to put more money in the market. Wealthy Americans are concerned about the political environment and US-China trade tensions but we are encouraged that they see diversification as an important way of managing

Andersen Global Expands into Ghana23.7.2019 13:30:00 CESTPress release

Ghana law firm, Sam Okudzeto & Associates, signed a collaboration agreement with Andersen Global, marking Andersen Global’s presence in 13 African countries and over 51 countries worldwide. Located in the capital of Accra, Sam Okudzeto & Associates is one of the largest law firms in Ghana. For the past 48 years, the firm has provided legal advice and guidance in the corporate and commercial areas, including patents and trademarks, mergers and acquisition, tax advisory, corporate banking, international trade and investment, debt recovery, mining and mineral law, industrial and labor, aviation, maritime law, petroleum oil and gas, and intellectual property. Sam Okudzeto & Associates founder and Managing Partner, Sam Okudzeto and Nene Amegatcher, have led the team since the establishment of the firm until Nene Amegatcher was elevated to the Supreme Court. The firm now has four partners and 18 lawyers who have gained international reputation for their keen knowledge and experience with Alt

Seoul Semiconductor Switches to Rimini Street for SAP Support23.7.2019 13:00:00 CESTPress release

Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced that Seoul Semiconductor, a global LED development and manufacturing company headquartered in South Korea, has switched from SAP to Rimini Street for support of its SAP ECC 6.0 system. As a result, Seoul Semiconductor has been able to reduce its annual maintenance fee by 50%, enjoy better support and can continue operating its stable, robust ERP ECC 6.0 system for a minimum of 15 additional years from the date the company switched to Rimini Street to retain full support without any forced upgrades or product migrations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190723005031/en/ Seoul Semiconductor, a global LED development and manufacturing company headquartered in South Korea, has switched from SAP to R